AKTX — Akari Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Akari Therapeutics Announces Preclinical Data On AKTX-101 For Pancreatic Cancer
Brief: Akari Therapeutics Provides Corporate Update
Brief: Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag As Interim Chief Financial Officer
On October 22 Appointed Kameel Farag As Interim CFO - SEC Filing
Brief: Akari Therapeutics Announces Launch of CEO Corner Platform
Brief: Akari Therapeutics To Present Oral Abstract At SITC’S 40th Annual Meeting
Brief: Akari Therapeutics' Preclinical Data Demonstrates The Potential Of Its Novel ADC Spliceosome Modulating Payload, Ph1
Brief: Akari Therapeutics PLC Enters Ordinary Share Purchase Agreement With White Lion Capital
Akari Therapeutics PLC expected to post a loss of 11 cents a share - Earnings Preview
Brief: Akari Therapeutics PLC Files For Mixed Shelf Of Up To $75 Million – SEC Filing
Brief: Akari Therapeutics Cash On Hand Expected To Be Sufficient To Fund Planned Operations Into September 2025
Brief: Akari Therapeutics Announces $7.6 Million Private Placement Offering
Brief: Akari Therapeutics Announces Key Leadership Appointments
Brief: Akari Therapeutics Regains Full Nasdaq Compliance
Brief: Akari Therapeutics Announces Shareholder Approval In Connection With Peak Bio Merger
Brief: Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy
Brief: Charles Steve Theofilos Files To Report Stake Of 9.99% In Akari Therapeutics PLC As Of May 31, 2024 - SEC Filing
Brief: Akari Therapeutics Secures $7.6 Million in Upsized Financing Round
U.S. STOCKS ON THE MOVE-Salesforce, Birkenstock, Kohls Corp